The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers

PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy

(2015) François Bertucci et al.   Oncotarget

Prognostic and predictive value of PDL1 expression in breast cancer

(2015) Renaud Sabatier et al.   Oncotarget

Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications

(2015) Aitziber Buqué et al.   OncoImmunology

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

(2014) S. Loi et al.   ANNALS OF ONCOLOGY

Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer

(2014) S. Muenst et al.   BREAST CANCER RESEARCH AND TREATMENT

In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas

(2014) K. A. Schalper et al.   CLINICAL CANCER RESEARCH

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma

(2011) Jocelyne Jacquemier et al.   INTERNATIONAL JOURNAL OF CANCER

Kinome expression profiling and prognosis of basal breast cancers

(2011) Renaud Sabatier et al.   Molecular Cancer